PolarityTE to Report Q1 2021 Financial Results on May 16, 2022

Rhea-AI Summary

PolarityTE, Inc. (Nasdaq: PTE) is set to release its financial results for the quarter ending March 31, 2022, on May 16, 2022, at approximately 7:30 a.m. Eastern Time. A conference call with Q&A will follow at 8:30 a.m. Eastern Time. Investors can access the call by dialing 1-800-289-0459 and using passcode 399675. The company is developing SkinTE®, a regenerative tissue product, and is pursuing pivotal studies required for a biologics license application with the FDA.

Positive

• Upcoming earnings report on May 16, 2022, may provide insights into future growth.
• Ongoing development of SkinTE® could lead to significant advancements in regenerative medicine.

Negative

• None.

SALT LAKE CITY, May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May 16, 2022, at approximately 7:30 a.m. Eastern Time.

In addition, the Company will host a conference call and webcast with Q&A on May 16, 2022, at 8:30 a.m. Eastern Time.  The conference call can be accessed by calling 1-800-289-0459 with passcode 399675 and referencing "PolarityTE First Quarter 2022 Business Update".  A webcast of the conference call can be accessed by using the link below.

Earnings Call Webcast - CLICK HERE

A replay of the earnings conference call will be available for 30 days, beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE's website at https://www.polarityte.com/news-media/events, or by clicking on the link above.

About PolarityTE®
PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products.  PolarityTE's first regenerative tissue product is SkinTE®.  PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA) for a chronic cutaneous ulcer indication.  SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.

POLARITYTE, the POLARITYTE logo, SKINTE, and WHERE SELF REGENERATES SELF are registered trademarks of PolarityTE, Inc.

CONTACTS

Investors:
PolarityTE Investor Relations
ir@PolarityTE.com
(385) 831-5284

Media:
David Schull or Ignacio Guerrero-Ros
David.schull@russopartnersllc.com 
Ignacio.guerrero-ros@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/polarityte-to-report-q1-2021-financial-results-on-may-16-2022-301541444.html

SOURCE PolarityTE, Inc.

FAQ

When will PolarityTE report its Q1 2022 financial results?

PolarityTE will report its Q1 2022 financial results on May 16, 2022.

What time is the PolarityTE conference call scheduled for?

The conference call is scheduled for 8:30 a.m. Eastern Time on May 16, 2022.

How can I access the earnings call for PolarityTE?

You can access the earnings call by calling 1-800-289-0459 with passcode 399675.

What is SkinTE® and its significance for PolarityTE?

SkinTE® is a regenerative tissue product currently under development by PolarityTE, aimed at treating chronic cutaneous ulcers.